HRP20171905B1 - Formulacije tpp1 i postupci liječenja bolesti cln2 - Google Patents

Formulacije tpp1 i postupci liječenja bolesti cln2 Download PDF

Info

Publication number
HRP20171905B1
HRP20171905B1 HRP20171905AA HRP20171905A HRP20171905B1 HR P20171905 B1 HRP20171905 B1 HR P20171905B1 HR P20171905A A HRP20171905A A HR P20171905AA HR P20171905 A HRP20171905 A HR P20171905A HR P20171905 B1 HRP20171905 B1 HR P20171905B1
Authority
HR
Croatia
Prior art keywords
concentration
rhtpp1
disease
cln2
patients
Prior art date
Application number
HRP20171905AA
Other languages
English (en)
Croatian (hr)
Inventor
Thomas W. Lester
Saeed Moshashaee
Augustus O. Okhamafe
Charles A. O'neill
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of HRP20171905A2 publication Critical patent/HRP20171905A2/hr
Publication of HRP20171905B1 publication Critical patent/HRP20171905B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
HRP20171905AA 2015-05-08 2016-05-05 Formulacije tpp1 i postupci liječenja bolesti cln2 HRP20171905B1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158789P 2015-05-08 2015-05-08
US201662300171P 2016-02-26 2016-02-26
PCT/US2016/031074 WO2016182862A1 (en) 2015-05-08 2016-05-05 Tpp1 formulations and methods for treating cln2 disease

Publications (2)

Publication Number Publication Date
HRP20171905A2 HRP20171905A2 (hr) 2018-05-18
HRP20171905B1 true HRP20171905B1 (hr) 2023-03-17

Family

ID=57222195

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20240050TT HRP20240050T1 (hr) 2015-05-08 2016-05-05 Formulacije tpp1 i postupci liječenja bolesti cln2
HRP20171905AA HRP20171905B1 (hr) 2015-05-08 2016-05-05 Formulacije tpp1 i postupci liječenja bolesti cln2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20240050TT HRP20240050T1 (hr) 2015-05-08 2016-05-05 Formulacije tpp1 i postupci liječenja bolesti cln2

Country Status (25)

Country Link
US (3) US10279015B2 (enExample)
EP (2) EP4327873A3 (enExample)
JP (3) JP6931330B2 (enExample)
KR (1) KR102375051B1 (enExample)
CN (2) CN107847615B (enExample)
AU (1) AU2016262434B2 (enExample)
CA (1) CA2984448A1 (enExample)
CL (1) CL2017002825A1 (enExample)
DK (1) DK3294345T3 (enExample)
ES (1) ES2968375T3 (enExample)
FI (1) FI3294345T3 (enExample)
HR (2) HRP20240050T1 (enExample)
HU (1) HUE065649T2 (enExample)
IL (3) IL255307B (enExample)
LT (1) LT3294345T (enExample)
MX (1) MX2017014204A (enExample)
PL (1) PL3294345T3 (enExample)
PT (1) PT3294345T (enExample)
RS (1) RS65101B1 (enExample)
RU (1) RU2733464C2 (enExample)
SI (1) SI3294345T1 (enExample)
SM (1) SMT202400026T1 (enExample)
TW (1) TWI752907B (enExample)
WO (1) WO2016182862A1 (enExample)
ZA (1) ZA201707373B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
EP3607320A4 (en) 2017-04-03 2021-04-21 The Regents of the University of California COMPOSITIONS AND METHODS OF DIAGNOSING Pancreatic Cancer
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CN113382683A (zh) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 改善睡眠的系统和方法
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
US20220381784A1 (en) * 2019-06-07 2022-12-01 The Regents Of The University Of California Systems comprising substrates and methods of using the same for detection of pancreatic cancers
SMT202400315T1 (it) * 2019-08-29 2024-09-16 Biomarin Pharm Inc Metodi per il trattamento della malattia cln2 in soggetti pediatrici
IT201900023142A1 (it) * 2019-12-05 2021-06-05 Sifi Spa Composizione topica oculare contenente metaboliti della fermentazione di lactobacillus
US20230060797A1 (en) * 2021-09-02 2023-03-02 Jcr Pharmaceuticals Co., Ltd. Therapeutic compound for neuronal ceroid lipofuscinosis
CN117731312A (zh) 2022-09-13 2024-03-22 上海联影医疗科技股份有限公司 一种医学图像的扫描方法和系统

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210604A1 (en) * 2007-06-13 2010-08-19 Meythaler Jay M Zwitterion solution for low-volume therapeutic delivery
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
US20110166074A1 (en) * 2006-10-18 2011-07-07 Cornell Research Foundation, Inc. Cln2 treatment of alzheimer's disease
US20120148558A1 (en) * 2003-08-29 2012-06-14 Biomarin Pharmaceutical Inc. Delivery of Therapeutic Compounds to the Brain and Other Tissues
WO2014085621A1 (en) * 2012-11-27 2014-06-05 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
WO2014089449A1 (en) * 2012-12-07 2014-06-12 Rush University Nedical Center Composition and method for treating neuronal ceroid lipofuscinosis
WO2015013148A2 (en) * 2013-07-26 2015-01-29 University Of Iowa Research Foundation Methods and compositions for treating brain diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302685B1 (en) 1997-09-16 2001-10-16 University Of Medicine And Dentistry Of New Jersey Human lysosomal protein and methods of its use
US20020006400A1 (en) 2000-05-11 2002-01-17 Peter Lobel Recombinant human CLN2 protein and methods of its production and use
MXPA03010341A (es) * 2001-05-18 2004-03-10 Solvay Pharm Gmbh Uso de compuestos con actividad inhibitoria de epn/mp combinada en la preparacion de medicamentos.
AU2002362436A1 (en) * 2001-10-03 2003-04-14 Rigel Pharmaceuticals, Inc. Modulators of lymphocyte activation and migration
CA2388659A1 (en) * 2002-05-31 2003-11-30 Mcgill University Phospholipase a2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease
WO2012015910A2 (en) * 2010-07-28 2012-02-02 Allon Therapeutics Inc. Use of adnf polypeptides for treating neurodegenerative diseases
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
US20150000936A1 (en) * 2011-12-13 2015-01-01 Schlumberger Technology Corporation Energization of an element with a thermally expandable material
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
TWI752907B (zh) 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120148558A1 (en) * 2003-08-29 2012-06-14 Biomarin Pharmaceutical Inc. Delivery of Therapeutic Compounds to the Brain and Other Tissues
US20110166074A1 (en) * 2006-10-18 2011-07-07 Cornell Research Foundation, Inc. Cln2 treatment of alzheimer's disease
US20100210604A1 (en) * 2007-06-13 2010-08-19 Meythaler Jay M Zwitterion solution for low-volume therapeutic delivery
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
US20120308544A1 (en) * 2009-12-14 2012-12-06 Robert Steinfeld Substances and Methods for the Treatment of Lysosmal Storage Diseases
WO2014085621A1 (en) * 2012-11-27 2014-06-05 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
WO2014089449A1 (en) * 2012-12-07 2014-06-12 Rush University Nedical Center Composition and method for treating neuronal ceroid lipofuscinosis
WO2015013148A2 (en) * 2013-07-26 2015-01-29 University Of Iowa Research Foundation Methods and compositions for treating brain diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Brian R Vuillemenot et al, "Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis", Molecular Genetics and Metabolism, vol. 104, no. 3, (2011) str. 325 - 337, 30.06.2011. doi: https://doi.org/10.1016/j.ymgme.2011.06.018 *

Also Published As

Publication number Publication date
IL299024B2 (en) 2025-12-01
US10279015B2 (en) 2019-05-07
EP4327873A2 (en) 2024-02-28
SI3294345T1 (sl) 2024-03-29
US10758598B2 (en) 2020-09-01
RS65101B1 (sr) 2024-02-29
MX2017014204A (es) 2018-07-06
CN114225018A (zh) 2022-03-25
KR102375051B1 (ko) 2022-03-15
JP2024026739A (ja) 2024-02-28
SMT202400026T1 (it) 2024-03-13
TW201704469A (zh) 2017-02-01
US20200353059A1 (en) 2020-11-12
IL299024B1 (en) 2025-08-01
AU2016262434A1 (en) 2017-11-16
CN107847615A (zh) 2018-03-27
IL273913B2 (en) 2023-06-01
RU2733464C2 (ru) 2020-10-01
JP6931330B2 (ja) 2021-09-01
EP3294345A4 (en) 2019-01-16
BR112017023805A2 (pt) 2018-07-31
TWI752907B (zh) 2022-01-21
JP2021175760A (ja) 2021-11-04
AU2016262434B2 (en) 2022-06-02
CN107847615B (zh) 2022-01-25
PT3294345T (pt) 2024-01-18
EP4327873A3 (en) 2024-05-01
WO2016182862A1 (en) 2016-11-17
CL2017002825A1 (es) 2018-06-22
HK1250479A1 (en) 2018-12-21
US11229687B2 (en) 2022-01-25
RU2017142727A3 (enExample) 2019-12-11
DK3294345T3 (da) 2024-01-22
PL3294345T3 (pl) 2024-07-01
ZA201707373B (en) 2019-02-27
HUE065649T2 (hu) 2024-06-28
JP7421520B2 (ja) 2024-01-24
FI3294345T3 (fi) 2024-01-15
US20160324942A1 (en) 2016-11-10
IL273913A (en) 2020-05-31
KR20180004158A (ko) 2018-01-10
CA2984448A1 (en) 2016-11-17
RU2017142727A (ru) 2019-06-10
EP3294345A1 (en) 2018-03-21
EP3294345B1 (en) 2023-10-18
HRP20240050T1 (hr) 2024-03-29
HRP20171905A2 (hr) 2018-05-18
LT3294345T (lt) 2024-02-12
US20190216905A1 (en) 2019-07-18
IL255307A0 (en) 2017-12-31
ES2968375T3 (es) 2024-05-09
JP2018521964A (ja) 2018-08-09
IL255307B (en) 2021-03-25
IL299024A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
US11229687B2 (en) TPP-1 formulations and methods for treating CLN2 disease
EP4021575B1 (en) Methods for treating cln2 disease in pediatric subjects
RU2848083C1 (ru) Способы лечения заболевания cln2 у детей
HK40107015A (en) Tpp1 formulations and methods for treating cln2 disease
HK40117495A (en) Methods for treating cln2 disease in pediatric subjects
HK1250479B (en) Tpp1 formulations and methods for treating cln2 disease
BR112017023805B1 (pt) Formulações e composições de tpp1, bem como uso no tratamento de doença lcn2
HK40077045A (en) Methods for treating cln2 disease in pediatric subjects
HK40077045B (en) Methods for treating cln2 disease in pediatric subjects
BR122025005065A2 (pt) Formulações e composições de tpp1, bem como uso no tratamento de doença lcn2

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190503

Year of fee payment: 4

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200422

Year of fee payment: 5

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210421

Year of fee payment: 6

ODRP Renewal fee for the maintenance of a patent

Payment date: 20220503

Year of fee payment: 7

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20230502

Year of fee payment: 8

ODRP Renewal fee for the maintenance of a patent

Payment date: 20240424

Year of fee payment: 9

ODRP Renewal fee for the maintenance of a patent

Payment date: 20250428

Year of fee payment: 10